LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Biomarkers predicting the controller dose of omalizumab in patients with chronic spontaneous urticaria.

Zubiaga-Fernandez, L / Testera-Montes, A / Rondon, C / Perez-Sanchez, N / Gomez-Perez, F / Vega-Chicote, J M / Bartra, J / Ferrer, M / Eguiluz-Gracia, I / Torres, M J

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

2024

Abstract: Background: Clinical trials showed the efficacy of 300 mg/4 weeks of omalizumab (OMA) during 6 months in patients with severe chronic spontaneous urticaria (CSU). Nevertheless, in real life, many patients require higher doses and/or longer treatment. ... ...

Abstract	Background: Clinical trials showed the efficacy of 300 mg/4 weeks of omalizumab (OMA) during 6 months in patients with severe chronic spontaneous urticaria (CSU). Nevertheless, in real life, many patients require higher doses and/or longer treatment. This study assesses the real-life performance of OMA in severe CSU and identifies factors associated with the response. Methods: CSU patients eligible for OMA were recruited prospectively. Clinical data and a blood test were collected before OMA initiation. Urticaria Activity Score 7 (UAS7) was calculated at baseline and every 3 months during OMA treatment. CSU control was defined as UAS7 <7 points. This work was partially sponsored by OMA manufacturer. Results: Eighty-nine adults (19.1% males) with severe CSU were recruited. Median duration of CSU prior to OMA initiation was 2 years, and median severity by UAS7 at baseline was 24 points (range 10-42 points). OMA controlled 94.4% of patients, but 17.9% of responders required doses >300 mg/4 weeks. A blood basophil count >20 cells/μL (OR 13.33; 95% CI 3.32-52.63; p < .001) and the absence of hypothyroidism (OR 3.65; 95% CI 0.78-16.95; p = .099) were identified as predictive factors to achieve control with 300 mg/4 weeks. Twelve patients were able to stop OMA during the study (responders in remission, RR). RR had received OMA for a median of 29 months (12-53 months). Conversely, 32 patients had been on OMA for >29 months at the end of the study (active responders, AR). AR had received OMA for a median of 45 months (30-100 months). There were no significant differences in clinical or analytical factors between RR and AR patients. Conclusions: Low blood basophil count and the presence of hypothyroidism might serve as biomarkers for the controller dose of OMA in severe CSU patients.
Language	English
Publishing date	2024-02-11
Publishing country	England
Document type	Journal Article
ZDB-ID	645204-8
ISSN	1365-2222 ; 0954-7894 ; 0960-2178
ISSN (online)	1365-2222
ISSN	0954-7894 ; 0960-2178
DOI	10.1111/cea.14462
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 767: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: The use of triple therapy in asthma. The GEMA-FORUM V task force.

Plaza, V / Trigueros, J A / Carretero, J A / Ojanguren Arranz, I / Vega Chicote, J M / Almonacid Sánchez, C / Bartra Tomás, J / Cisneros Serrano, C / Domínguez Juncal, L / Domínguez-Ortega, J / Figueroa Rivero, J / Soto Campos, J G / Macías Fernández, E / Martínez, S / Montoro Lacomba, J / Quirce, S

Journal of investigational allergology & clinical immunology

2024

Language	English
Publishing date	2024-02-09
Publishing country	Spain
Document type	Journal Article
ZDB-ID	1128657-x
ISSN	1018-9068
ISSN	1018-9068
DOI	10.18176/jiaci.0975
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3487: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Review of the Latest Recommendations on the Management of Chronic Urticaria: A Multidisciplinary Consensus Statement from Andalusia, Spain.

Alcántara Villar, M / Armario Hita, J C / Cimbollek, S / Fernández Ballesteros, M D / Galán Gutiérrez, M / Hernández Montoya, C / Lara-Jiménez, M Á / Pereyra Rodríguez, J J / Vega Chicote, J M / Ruiz-Villaverde, R

Actas dermo-sifiliograficas

2020 Volume 111, Issue 3, Page(s) 222–228

Abstract: Chronic urticaria is a difficult-to-treat skin disorder that has a major impact on patient quality of life. The latest update of the European guideline on the management of urticaria was published in 2018. In this consensus statement, produced in the ... ...

Title translation	Revisión de las últimas novedades en el manejo del paciente con urticaria crónica: Consenso multidisciplinar de la comunidad autónoma de Andalucía.
Abstract	Chronic urticaria is a difficult-to-treat skin disorder that has a major impact on patient quality of life. The latest update of the European guideline on the management of urticaria was published in 2018. In this consensus statement, produced in the autonomous community of Andalusia, Spain, we describe a multidisciplinary approach for applying the new treatment algorithm proposed by the European guideline in our region.
MeSH term(s)	Chronic Urticaria ; Consensus ; Humans ; Quality of Life ; Spain ; Urticaria/diagnosis
Language	Spanish
Publishing date	2020-01-23
Document type	Practice Guideline ; Review
ZDB-ID	2541876-2
ISSN	2173-5778 ; 2173-5778
ISSN (online)	2173-5778
ISSN	2173-5778
DOI	10.1016/j.ad.2019.04.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence.

Dominguez-Ortega, J / Delgado, J / Blanco, C / Prieto, L / Arroabarren, E / Cimarra, M / Henriquez-Santana, A / Iglesias-Souto, J / Vega-Chicote, J M / Tabar, A I

Journal of investigational allergology & clinical immunology

2017 Volume 27, Issue Suppl. 1, Page(s) 1–35

Abstract: Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and ... ...

Abstract	Asthma is frequently associated with atopy, characterized by the production of specific immunoglobulin E in response to environmental allergens. Currently, two types of allergen immunotherapy (AIT) are used in clinical practice: subcutaneous and sublingual immunotherapy, both accepted as key components of the therapeutic repertoire for allergic rhinitis and conjunctivitis. However, their role in asthma remains controversial. The present document is aimed at providing the clinicians with a review of the evidence on the use of AIT in asthma, focusing on the most relevant aspects of its mechanism of action, its efficacy, and existing data on safety, tolerability, and cost-effectivity, both in pediatric and adult populations. A systematic search of MEDLINE, Cochrane, and Clinical Trials databases from 2000 to April of 2016 was carried out by a panel of experts from the Spanish Allergy and Clinical Immunology Scientific Society. Relevant studies prior to the year 2000 included in ulterior systematic reviews were also considered. More than 4000 articles were identified during the search and 241 were selected to retrieve available evidence on AIT, which was graded according to the Oxford classification. All the group members reviewed the resulting text until the final version reached the consensual agreement. A summary of recommendations on the more relevant topics are proposed. The role of AIT as a valuable therapeutic strategy for prevention of exacerbation and progressive decline in lung function is highlighted. Future research should include specific tools for asthma evaluation when assessing AIT effectiveness in asthmatic patients.
MeSH term(s)	Adult ; Allergens/immunology ; Asthma/etiology ; Asthma/therapy ; Child ; Desensitization, Immunologic/methods ; Female ; Humans ; Hypersensitivity/complications ; Hypersensitivity/therapy ; Male
Chemical Substances	Allergens
Language	English
Publishing date	2017-06
Publishing country	Spain
Document type	Journal Article
ZDB-ID	1128657-x
ISSN	1018-9068
ISSN	1018-9068
DOI	10.18176/jiaci.0149
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3487: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma.

Ameal, A / Vega-Chicote, J M / Fernández, S / Miranda, A / Carmona, M J / Rondón, M C / Reina, E / García-González, J J

Allergy

2005 Volume 60, Issue 9, Page(s) 1178–1183

Abstract: Background: A randomized double-blind, placebo-controlled study was conducted in patients allergic asthma sensitized to Dermatophagoides pteronyssinus.: Objective: To evaluate the efficacy and safety after 1-year of immunotherapy with a modified D. ... ...

Abstract	Background: A randomized double-blind, placebo-controlled study was conducted in patients allergic asthma sensitized to Dermatophagoides pteronyssinus. Objective: To evaluate the efficacy and safety after 1-year of immunotherapy with a modified D. pteronyssinus extract compared with placebo. Material and methods: Fifty-five patients were randomly allocated to receive the active treatment (n = 29), or placebo (n = 26). The main outcome was the specific bronchial provocation test (BPT). Other parameters analysed were dose-response skin prick test (SPT), symptom and medication scores and asthma quality of life (AQLQ). Results: At the end of the study, the active group showed a significant increase in the PD(20)FEV(1) compared with placebo (P = 0.0029). Nineteen patients of the active vs 10 of the placebo group needed more than twice the initial amount of allergen extract to have a positive BPT (P = 0.0293); seven patients in the placebo vs one in the active group needed less than half (P = 0.0137). In SPT, a significant improvement (P = 0.0049) was found in the active group. This group also had a median reduction of 91.5% in symptom scores, whereas the placebo group increased by 86%. Medication scores decreased in both groups (56% in the active and 11.4% in the placebo). In AQLQ, the differences between both groups were significant (P = 0.0234) at the end of the study. Conclusion: After 1 year of treatment, the modified extract of D. pteronyssinus demonstrated to be safe and efficacious to treat patients with asthma and allergic rhinoconjunctivitis sensitized to this mite.
MeSH term(s)	Adolescent ; Adult ; Allergens/immunology ; Antigens, Dermatophagoides/immunology ; Asthma/immunology ; Asthma/therapy ; Bronchial Provocation Tests ; Conjunctivitis, Allergic/immunology ; Conjunctivitis, Allergic/therapy ; Desensitization, Immunologic/methods ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Rhinitis, Allergic, Perennial/immunology ; Rhinitis, Allergic, Perennial/therapy ; Skin Tests ; Treatment Outcome
Chemical Substances	Allergens ; Antigens, Dermatophagoides
Language	English
Publishing date	2005-09
Publishing country	Denmark
Document type	Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
ZDB-ID	391933-x
ISSN	1398-9995 ; 0105-4538
ISSN (online)	1398-9995
ISSN	0105-4538
DOI	10.1111/j.1398-9995.2005.00862.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.150: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 125: Show issues

Order via subito

Details ▾

Article: Cistus ladanifer contact dermatitis.

García-González, J J / Crespo, V / Barber, D / Miranda, A / Vega-Chicote, J M / Carmona, M J / Negro, M A / Lombardero, M / Ameal, A / Barceló-Muñoz, J M

Contact dermatitis

2001 Volume 45, Issue 4, Page(s) 238

MeSH term(s)	Adult ; Cistus/adverse effects ; Dermatitis, Allergic Contact/etiology ; Hand Dermatoses/etiology ; Humans ; Male ; Patch Tests
Language	English
Publishing date	2001-10
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	193121-0
ISSN	1600-0536 ; 0105-1873
ISSN (online)	1600-0536
ISSN	0105-1873
DOI	10.1034/j.1600-0536.2001.450412.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1116: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Prevalence of atopy in students from Málaga, Spain.

García-González, J J / Vega-Chicote, J M / Rico, P / del Prado, J M / Carmona, M J / Miranda, A / Pérez-Estrada, M / Martin, S / Cervera, J A / Acebes, J M

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

1998 Volume 80, Issue 3, Page(s) 237–244

Abstract: Background: Epidemiologic studies are necessary to determine the prevalence of allergic diseases. This varies widely depending on allergen preparations and patients studied.: Objective: To investigate the prevalence of atopic disease, skin test ... ...

Abstract	Background: Epidemiologic studies are necessary to determine the prevalence of allergic diseases. This varies widely depending on allergen preparations and patients studied. Objective: To investigate the prevalence of atopic disease, skin test reactivity, total and specific IgE to common allergens, and other variables in a sample of students from Málaga, southern Spain. Methods: Three hundred sixty-five students (age 17.9 +/- 1.18) were interviewed by an allergist. Skin prick tests were performed with Dermatophagoides pteronyssinus, Artemisia vulgaris, Plantago lanceolata, Chenopodium album, Olea europaea, Phleum pratense, Parietaria judaica, Cynodon dactylon, Alternaria tenuis, and cat dander. Total and specific IgE to D. pteronyssinus, Olea, and Parietaria were determined. Results: Of all subjects studied, 19.9% suffered from rhinoconjunctivitis, 4.1% rhinoconjunctivitis plus asthma, 3.1% asthma alone, and 0.8% atopic dermatitis; 46.4% had a positive skin test to at least one allergen (28.2% to D. pteronyssinus, 20.4% to Olea, 13.8% to Phleum); and 43% had total IgE > 100 kU/L and 44.7% a family history of atopy. Allergic symptoms were strongly associated with skin test positivities and family allergic history. Patients with asthma or skin prick test positive had higher total IgE values than others (P < .01). There was a significant correlation between specific IgE values and wheal size in skin test. Conclusions: Our findings confirm the high prevalence of atopic diseases, and the close relationship of skin tests reactivity (or presence of specific IgE) to allergens with symptoms of asthma and rhinitis. The presence of a family history of allergic diseases influences the development of positive skin tests and atopic illness. Dermatophagoides pteronyssinus and pollen of Olea europaea were found to be the most common allergens.
MeSH term(s)	Adolescent ; Adult ; Animals ; Cats ; Dust ; Female ; Humans ; Hypersensitivity/epidemiology ; Immunoglobulin E/blood ; Male ; Mites/immunology ; Prevalence ; Skin Tests ; Spain/epidemiology
Chemical Substances	Dust ; Immunoglobulin E (37341-29-0)
Language	English
Publishing date	1998-03
Publishing country	United States
Document type	Journal Article
ZDB-ID	1228189-x
ISSN	1534-4436 ; 1081-1206 ; 0003-4738
ISSN (online)	1534-4436
ISSN	1081-1206 ; 0003-4738
DOI	10.1016/s1081-1206(10)62964-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.136: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Pollinosis to Ricinus communis (castor bean): an aerobiological, clinical and immunochemical study.

García-González, J J / Bartolomé-Zavala, B / Del Mar Trigo-Pérez, M / Barceló-Muñoz, J M / Fernández-Meléndez, S / Negro-Carrasco, M A / Carmona-Bueno, M J / Vega-Chicote, J M / Muñoz-Román, C / Palacios-Peláez, R / Cabezudo-Artero, B / Martínez-Quesada, J

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

1997 Volume 29, Issue 9, Page(s) 1265–1275

Abstract: Background: Ricinus communis (castor bean) is a species included into the Euphorbiaceae family, common to all the warm regions of the world. Although the allergenicity of its seed is well known, references are scarce regarding the role played by its ... ...

Abstract	Background: Ricinus communis (castor bean) is a species included into the Euphorbiaceae family, common to all the warm regions of the world. Although the allergenicity of its seed is well known, references are scarce regarding the role played by its pollen as a pneumo-allergen. Objectives: To carry out an aerobiological study of this pollen in the Málaga area (southern Spain); describe the physicochemical characteristics of its most relevant allergens; and to demonstrate the existence of patients with respiratory allergy due to this pollen. Methods: A Burkard spore trap was used for the aerobiological study from 1992 to 1996. Skin prick tests with castor bean pollen extract were performed to 1946 patients with rhinitis and/or asthma. Specific IgE levels were measured in castor bean-positive SPT patient sera. Immunochemical characterization of the most relevant allergens was performed using electrophoretic techniques. In vitro cross-reactivity studies using positive patient sera were carried out. Nasal challenge tests were done in 32 subjects randomly selected from the sensitized patient group. Results: Castor bean is a perennial pollen with total annual pollen levels never exceeding 1%. One hundred and eighteen (7.7%) patients showed positive prick test (74 rhinitis, 36 rhinitis and asthma, eight asthma). Nine were monosensitized. Specific IgE levels were > or =0.35 PRU/mL in 39 (33%) of patient sera. Nasal challenge test: 10 subjects presented non-specific nasal hyperactivity, 15 were positive and seven negative. The molecular masses and isoelectric points of the main IgE-binding proteins, ranged from approximately 67-15.5/14.5 kDa and approximately 4.5-5.5, respectively. Profilin of the extract was purified by poli-L-proline-Sepharose chromatography and it appeared as one of the most frequent allergens. Conclusion: Castor bean pollen is an allergen which causes respiratory (mainly nasal) symptoms.
MeSH term(s)	Adolescent ; Adult ; Air Pollution/analysis ; Allergens/adverse effects ; Asthma/etiology ; Asthma/immunology ; Ricinus communis/adverse effects ; Ricinus communis/physiology ; Cross Reactions ; Environmental Monitoring ; Humans ; Male ; Middle Aged ; Nasal Provocation Tests ; Plant Extracts/chemistry ; Plant Extracts/immunology ; Plants, Toxic ; Pollen/adverse effects ; Pollen/physiology ; Radioallergosorbent Test ; Rhinitis, Allergic, Perennial/etiology ; Rhinitis, Allergic, Perennial/immunology ; Skin Tests
Chemical Substances	Allergens ; Plant Extracts
Language	English
Publishing date	1997-04-01
Publishing country	England
Document type	Journal Article
ZDB-ID	645204-8
ISSN	1365-2222 ; 0954-7894 ; 0960-2178
ISSN (online)	1365-2222
ISSN	0954-7894 ; 0960-2178
DOI	10.1046/j.1365-2222.1999.00601.x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 767: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito